Immune-cell Functional Profiling Sheds Light on the Pathogenesis of Severe COVID-19

In a paper published in Immunity, researchers P. Szabo et al. used IsoPlexis’ Functional Proteomics to indicate that promoting lung-localized immune responses could be a viable alternative vaccination strategy for individuals, such as the immunocompromised or elderly, who are unable to develop effective systemic antibody responses.

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this we discuss:

The mechanisms behind pathogenic immune responses 
An airway-specific cell signature 
Airway immune cells work to create a pro-inflammatory environment
A better understanding leads to more effective therapeutic strategies
A Deeper Look

More about this

As of April 2021, COVID-19 has resulted in over two million deaths worldwide.

Immune response dysfunction has been implicated in severe COVID-19. However, the precise nature of these pathogenic systemic immune responses remains unclear.

In this study, published in Immunity, researchers used high-dimensional phenotypic, transcriptomic, and functional profiling techniques to identify key disease drivers in patients with severe COVID-19.

The study found evidence for myeloid cell-driven lung inflammation in severe COVID-19 and revealed potential therapeutic targets for reducing lung damage by inhibiting airway-specific inflammatory processes.

Download this Paper Summary to see the full findings!

awards-bar-3-wide-color-right
awards-bar-4-wide-color-left
Get the